Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III, the Board of Directors at their meeting ....
Awaiting price reaction for this filing.
The Board of Directors of Kashyap Tele-Medicines Limited (Scrip Code: 531960) met on 23rd May 2025 and approved audited financial results for Q4 and FY ended 31st March 2025 along with an unmodified auditor's opinion from M/s. Ravi Karia & Associates. Total revenue for FY25 was Rs. 19.21 lakhs, essentially flat compared to Rs. 19.21 lakhs in FY24, while the net loss narrowed sharply to Rs. 0.03 lakhs from Rs. 3.00 lakhs in the previous year. Cash flow from operations was negative at Rs. (8.60) lakhs versus Rs. (0.34) lakhs last year, and other equity remains deeply negative at Rs. (413.29) lakhs. The Board also accepted the resignations of Managing Director Amit Agrawal, Director and CFO Raghav Agrawal, and Director Ayushman Khemka, all citing pre-occupation effective 24th May 2025. In their place, Kalpesh Bipin Sheth was appointed as Managing Director, Heena Kalpesh Sheth as Whole-time Director, and Samir Ambavi as Additional Non-executive Director, all subject to shareholder approval.
Shareholders should note the simultaneous exit of the Managing Director, CFO, and a Director — a major leadership turnover that may raise governance concerns despite the 'pre-occupation' explanation. The company's financials show it is barely operational with negligible revenue, persistent losses, negative reserves, and worsening operating cash burn, making this a small-cap stock with significant fundamental weakness.